Bio-Techne Announces Investor Conference Presentations
MINNEAPOLIS, Nov. 8, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:
Investor Conference Schedule
UBS Global Healthcare Conference
November 12, 2024
9:30 AM PST
Stifel 2024 Healthcare Conference
November 19, 2024
8:00 AM EST
Stephens NASH 2024 Conference
November 20, 2024
11:00 AM CST
A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.
As Bio-Techne gears up to present at these investor conferences, the company is poised to showcase its latest developments and innovations in the life sciences industry. This is an opportunity for investors, stakeholders, and industry experts to gain insights into Bio-Techne’s future strategies and growth prospects.
How It Will Affect Me
For individual investors, attending or tuning in to these presentations can provide valuable information on Bio-Techne’s performance, potential investment opportunities, and overall market trends in the life sciences sector. Keeping abreast of such updates can help investors make informed decisions about their portfolios and investment strategies.
How It Will Affect the World
On a larger scale, Bio-Techne’s presence at these investor conferences signifies the company’s contribution to advancing scientific research and healthcare initiatives globally. By showcasing their innovative tools and bioactive reagents, Bio-Techne is paving the way for cutting-edge discoveries and breakthroughs in the field of life sciences.
Conclusion
Overall, Bio-Techne’s participation in these investor conferences marks a significant milestone in the company’s journey towards shaping the future of life sciences. As they continue to drive innovation and excellence in the industry, Bio-Techne remains a key player in advancing research and diagnostics for the betterment of society as a whole.
